Jeremiah Faith

Search results

• New Ulcerative Colitis Study Findings Have Been Reported by Investigators at Icahn School of Medicine at Mount Sinai (The Appendix and Ulcerative Colitis - an Unsolved Connection)

  Jeremiah Faith & Saurabh Mehandru

  23/05/23

  1 item of Media coverage

  Press/Media

• New Findings on Life Science from Icahn School of Medicine at Mount Sinai Summarized (Human Gut Microbiota Stimulate Defined Innate Immune Responses That Vary From Phylum To Strain)

  Ilaria Mogno, Jeremiah Faith & Saurabh Mehandru

  31/01/23

  1 item of Media coverage

  Press/Media

• Reports Outline Multiple Sclerosis Study Results from Icahn School of Medicine at Mount Sinai (Mining the Microbiota To Identify Gut Commensals Modulating Neuroinflammation In a Mouse Model of Multiple Sclerosis)

  Jeremiah Faith & Stephanie Tankou

  15/11/22

  1 item of Media coverage

  Press/Media

• Australia Patent: Icahn School of Medicine at Mount Sinai Files Application for 'Compositions and methods for treating inflammatory bowel disease'

  Jeremiah Faith

  29/07/22

  1 item of Media coverage

  Press/Media

• Finding Could Pave the Way to New, Targeted Antibody Treatments

  Jeremiah Faith

  8/07/22

  1 item of Media coverage

  Press/Media

• Microbes Behind Successful Fecal Microbiota Transplantations May Become Basis for New Treatments

  Jeremiah Faith

  28/09/21

  1 item of Media coverage

  Press/Media

• Potential alterative to FMT in bacteria may restore gut microbiome

  Jeremiah Faith

  27/09/21

  1 item of Media coverage

  Press/Media

• PureTech Health PLC First Patient in Vedanta Food Allergy Study

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study; First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history o

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• PureTech Health PLC First Patient in Vedanta Food Allergy Study

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• PureTech Health PLC First Patient in Vedanta Food Allergy Study

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study; First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history o

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

  Jeremiah Faith

  1/07/19

  4 items of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

  Jeremiah Faith

  1/07/19

  2 items of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

  Jeremiah Faith

  1/07/19

  4 items of Media coverage

  Press/Media

• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

  Jeremiah Faith

  1/07/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35

  Jeremiah Faith

  25/06/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35

  Jeremiah Faith

  25/06/19

  1 item of Media coverage

  Press/Media

• Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35

  Jeremiah Faith

  25/06/19

  4 items of Media coverage

  Press/Media

• Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35

  Jeremiah Faith

  25/06/19

  4 items of Media coverage

  Press/Media